AOD-9604 vs Tesofensine: Research Comparison

AOD-9604 and Tesofensine are both studied in adipose-reduction research but operate at completely different levels. AOD-9604 acts peripherally on adipocyte lipolysis; Tesofensine acts centrally on appetite circuits via monoamine reuptake inhibition.

Mechanism of Action

AOD-9604 is a C-terminal HGH fragment (177-191) with disulfide bridge. AOD-9604 retains the lipolytic activity of the HGH C-terminal region without engaging the growth hormone receptor. Research focuses on β3-adrenergic-adjacent lipolysis and fat oxidation markers.

Tesofensine is a triple monoamine reuptake inhibitor (NE/DA/5-HT). Tesofensine inhibits reuptake of norepinephrine, dopamine, and serotonin, modulating central appetite circuits and sympathetic tone in research models.

Technical Comparison

| Parameter | AOD-9604 | Tesofensine | |---|---|---| | Class | C-terminal HGH fragment (177-191) with disulfide bridge | triple monoamine reuptake inhibitor (NE/DA/5-HT) | | Mechanism | AOD-9604 retains the lipolytic activity of the HGH C-terminal region without engaging the growth hormone receptor. | Tesofensine inhibits reuptake of norepinephrine, dopamine, and serotonin, modulating central appetite circuits and sympathetic tone in research models. | | Half-life (research models) | Short plasma half-life (~30 min) | Long half-life (~9 days), allowing daily dosing with stable plasma levels | | Typical research dosing | 250–500 mcg subcutaneous, daily | 0.25–1.0 mg oral, daily |

Comparative Findings

Tesofensine research has shown substantially larger effect sizes on body-weight endpoints than AOD-9604 in published comparative data — but with the trade-off of central nervous system pharmacology, including potential cardiovascular and mood-related signals. AOD-9604 has a cleaner peripheral profile but smaller magnitude effects.

When Researchers Choose AOD-9604

Researchers select AOD-9604 when peripheral lipolytic mechanisms are the focus, when a clean (non-CNS) pharmacology profile is required, or when studying HGH receptor-independent fragment activity.

When Researchers Choose Tesofensine

Researchers select Tesofensine when central appetite mechanisms or monoamine pharmacology are the focus, or when investigating models requiring larger weight-marker effects.

Frequently Asked Questions

Are they ever combined in research?

Combination studies are uncommon because the mechanisms are non-overlapping and the safety profile of dual central + peripheral intervention is poorly characterized.

Which has more published clinical-translation data?

Tesofensine has been studied in phase II human trials. AOD-9604 has trial data but failed to differentiate strongly from placebo on primary endpoints.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are not for human or veterinary consumption. AOD-9604 and Tesofensine are research chemicals and have not been approved by the FDA for any therapeutic indication.